Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial

The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferio...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 23; no. 4; pp. 479 - 490
Main Authors Tang, Ling-Long, Huang, Cheng-Long, Zhang, Ning, Jiang, Wei, Wu, Yi-Shan, Huang, Shao Hui, Mao, Yan-Ping, Liu, Qing, Li, Ji-Bin, Liang, Shao-Qiang, Qin, Guan-Jie, Hu, Wei-Han, Sun, Ying, Xie, Fang-Yun, Chen, Lei, Zhou, Guan-Qun, Ma, Jun
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2022
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. For the Chinese translation of the abstract see Supplementary Materials section.
AbstractList The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.BACKGROUNDThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.METHODSThis open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis).FINDINGSBetween Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis).Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma.INTERPRETATIONElective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma.Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.FUNDINGSun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.For the Chinese translation of the abstract see Supplementary Materials section.TRANSLATIONFor the Chinese translation of the abstract see Supplementary Materials section.
The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. For the Chinese translation of the abstract see Supplementary Materials section.
SummaryBackgroundThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. MethodsThis open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. FindingsBetween Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; p non-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). InterpretationElective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. FundingSun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. TranslationFor the Chinese translation of the abstract see Supplementary Materials section.
The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; p <0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma. Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. For the Chinese translation of the abstract see Supplementary Materials section.
Summary Background The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. Methods This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Findings Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Interpretation Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. Funding Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. Translation For the Chinese translation of the abstract see Supplementary Materials section.
Author Sun, Ying
Mao, Yan-Ping
Hu, Wei-Han
Zhou, Guan-Qun
Qin, Guan-Jie
Jiang, Wei
Wu, Yi-Shan
Chen, Lei
Liang, Shao-Qiang
Xie, Fang-Yun
Huang, Cheng-Long
Li, Ji-Bin
Liu, Qing
Huang, Shao Hui
Ma, Jun
Tang, Ling-Long
Zhang, Ning
Author_xml – sequence: 1
  givenname: Ling-Long
  surname: Tang
  fullname: Tang, Ling-Long
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 2
  givenname: Cheng-Long
  surname: Huang
  fullname: Huang, Cheng-Long
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 3
  givenname: Ning
  surname: Zhang
  fullname: Zhang, Ning
  organization: Department of Radiation Oncology, First People's Hospital of Foshan, Foshan, China
– sequence: 4
  givenname: Wei
  surname: Jiang
  fullname: Jiang, Wei
  organization: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China
– sequence: 5
  givenname: Yi-Shan
  surname: Wu
  fullname: Wu, Yi-Shan
  organization: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 6
  givenname: Shao Hui
  surname: Huang
  fullname: Huang, Shao Hui
  organization: Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
– sequence: 7
  givenname: Yan-Ping
  surname: Mao
  fullname: Mao, Yan-Ping
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 8
  givenname: Qing
  surname: Liu
  fullname: Liu, Qing
  organization: Clinical Trials Centre, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 9
  givenname: Ji-Bin
  surname: Li
  fullname: Li, Ji-Bin
  organization: Clinical Trials Centre, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 10
  givenname: Shao-Qiang
  surname: Liang
  fullname: Liang, Shao-Qiang
  organization: Department of Radiation Oncology, First People's Hospital of Foshan, Foshan, China
– sequence: 11
  givenname: Guan-Jie
  surname: Qin
  fullname: Qin, Guan-Jie
  organization: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China
– sequence: 12
  givenname: Wei-Han
  surname: Hu
  fullname: Hu, Wei-Han
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 13
  givenname: Ying
  surname: Sun
  fullname: Sun, Ying
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 14
  givenname: Fang-Yun
  surname: Xie
  fullname: Xie, Fang-Yun
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 15
  givenname: Lei
  surname: Chen
  fullname: Chen, Lei
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 16
  givenname: Guan-Qun
  surname: Zhou
  fullname: Zhou, Guan-Qun
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
– sequence: 17
  givenname: Jun
  surname: Ma
  fullname: Ma, Jun
  email: majun2@mail.sysu.edu.cn
  organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35240053$$D View this record in MEDLINE/PubMed
BookMark eNqNkstu1DAUhiNURC_wCCBLbIo0AV8n0yJAqCoXqRILYG05zgnj1mMH2xk0j8bbcWZSuhgJlVUi6_u_HJ8_x9VBiAGq6imjLxll81dfmWxozalUp5y_oJSqRS0fVEd4LGslF4uD3fuEHFbHOV9TyhpG1aPqUCguMSGOqt-XHmxxayDjMECqA9gbsoaUx0x-LaOH6cSlZDpniouBxJ6UJfLBhXX0a-jIhAQyIAChYNKVJQkmx2Fp0ib8AOOJNcm6EFfmnBiUDBBqb1rwM4I3q13oIbmYXNnMyGr0xVk0JZiRZEIXVy7jd9CWgQhSkjP-cfWwNz7Dk9vnSfX9w-W3i0_11ZePny_eX9VWUV7qhbGcNVII2VqmeN9zzhaiAaoUFwJkK89EcybmtOtZ03aibztjO8WhFVZ1Cy5OqtPJO6T4c4RcNA5jwXsTII5Z87mYM8kUpYg-30Ov45gCToeUxBkahJB6dkuN7Qo6PSS3wi3pv6UgoCbApphzgv4OYVRvy9e78vW2Wc253pWvJeZe7-WsK7vOSjLO35t-N6UBl7l2kHS22KaFziX8RXQX3b2Gt3sG611w1vgb2EC-2wXTGUOTZOvgfGfYCt78W_AfA_wBDCTyrA
CitedBy_id crossref_primary_10_1016_S1470_2045_22_00262_5
crossref_primary_10_1016_j_radonc_2022_10_034
crossref_primary_10_1002_pro6_1219
crossref_primary_10_1007_s44178_023_00045_w
crossref_primary_10_1016_j_radonc_2023_109595
crossref_primary_10_1007_s00066_022_01986_3
crossref_primary_10_1186_s12885_024_12391_7
crossref_primary_10_1001_jamanetworkopen_2022_55209
crossref_primary_10_1016_j_radonc_2024_110225
crossref_primary_10_3389_fmed_2022_996127
crossref_primary_10_1007_s00761_024_01657_1
crossref_primary_10_1016_j_media_2024_103103
crossref_primary_10_1038_s41597_024_03890_0
crossref_primary_10_1186_s12885_025_13865_y
crossref_primary_10_1200_JCO_23_02086
crossref_primary_10_1016_j_semradonc_2025_01_001
crossref_primary_10_1245_s10434_024_16145_4
crossref_primary_10_3390_cancers16020383
crossref_primary_10_1016_j_semradonc_2025_01_003
crossref_primary_10_1186_s13643_022_02123_y
crossref_primary_10_3390_cancers15030672
crossref_primary_10_1016_j_radonc_2025_110713
crossref_primary_10_1016_j_radonc_2022_11_005
crossref_primary_10_1186_s12885_023_11212_7
crossref_primary_10_1177_03008916231154765
crossref_primary_10_1016_j_crad_2024_01_017
crossref_primary_10_1016_j_radonc_2023_110032
crossref_primary_10_1016_S1470_2045_22_00263_7
crossref_primary_10_1016_j_ijrobp_2023_02_047
crossref_primary_10_1002_cam4_6723
crossref_primary_10_1016_S1470_2045_22_00096_1
crossref_primary_10_3390_cancers14235773
crossref_primary_10_1097_MOO_0000000000000942
crossref_primary_10_1016_S1470_2045_22_00282_0
crossref_primary_10_1016_j_radonc_2024_110086
crossref_primary_10_1016_j_xcrm_2024_101594
crossref_primary_10_1016_j_eswa_2024_125208
crossref_primary_10_1002_pro6_70007
crossref_primary_10_1360_SSV_2024_0275
crossref_primary_10_3390_cancers16112085
crossref_primary_10_1016_j_critrevonc_2023_103994
crossref_primary_10_1016_j_radonc_2022_109447
crossref_primary_10_1016_j_radonc_2023_109860
crossref_primary_10_1038_s41415_022_5195_5
crossref_primary_10_1007_s44178_023_00046_9
crossref_primary_10_3390_jcm11123297
crossref_primary_10_1016_j_oraloncology_2022_106022
crossref_primary_10_1016_j_ijrobp_2022_12_041
crossref_primary_10_1158_1078_0432_CCR_23_3274
crossref_primary_10_1016_j_prro_2022_04_005
crossref_primary_10_1111_ajco_13955
crossref_primary_10_1136_bmj_2022_072133
crossref_primary_10_20960_revcancer_00070
Cites_doi 10.1016/S1470-2045(18)30104-9
10.5732/cjc.012.10095
10.1016/j.jclinepi.2010.11.016
10.1016/S0140-6736(18)32752-1
10.1016/S0140-6736(19)30956-0
10.1016/S1470-2045(21)00075-9
10.1245/s10434-011-2018-3
10.3322/caac.21492
10.1016/j.ijrobp.2010.03.024
10.1002/cncr.24049
10.1136/bmjopen-2020-044480
10.1016/j.radonc.2020.03.012
10.1016/j.radonc.2012.12.014
10.1200/JCO.2008.19.9109
10.1016/0360-3016(95)00060-C
10.1002/(SICI)1097-0347(200005)22:3<275::AID-HED10>3.0.CO;2-N
10.1002/cncr.31741
10.1007/s12094-018-1988-z
10.1016/0360-3016(93)90493-F
10.2307/2531021
10.1016/0360-3016(92)90740-9
10.1016/j.oraloncology.2017.03.010
10.1200/JCO.20.03237
10.1002/hed.23314
10.1016/j.radonc.2013.10.010
10.1016/j.oraloncology.2015.10.020
10.12788/j.suponc.0005
10.1016/j.ijrobp.2017.03.007
10.6004/jnccn.2017.0121
10.1002/cncr.28201
ContentType Journal Article
Copyright 2022 Elsevier Ltd
Elsevier Ltd
Copyright © 2022 Elsevier Ltd. All rights reserved.
2022. Elsevier Ltd
Copyright_xml – notice: 2022 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2022 Elsevier Ltd. All rights reserved.
– notice: 2022. Elsevier Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
0TZ
3V.
7RV
7TO
7X7
7XB
88E
8AO
8C1
8C2
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1016/S1470-2045(22)00058-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Pharma and Biotech Premium PRO
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Lancet Titles
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Pharma and Biotech Premium PRO
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
Lancet Titles
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



MEDLINE
Pharma and Biotech Premium PRO
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-5488
EndPage 490
ExternalDocumentID 35240053
10_1016_S1470_2045_22_00058_4
S1470204522000584
1_s2_0_S1470204522000584
Genre Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.
GroupedDBID ---
--K
--M
-RU
.1-
.55
.FO
0R~
123
1B1
1P~
1~5
29L
4.4
457
4CK
4G.
53G
5VS
6PF
7-5
71M
7RV
7X7
88E
8AO
8C1
8C2
8FI
8FJ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABUWG
ABWVN
ACGFS
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFKRA
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AHMBA
AIGII
AIIUN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BENPR
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
HMCUK
HVGLF
HZ~
IHE
J1W
KOM
M1P
M41
MO0
N9A
NAPCQ
O-L
O9-
OC~
OO-
OZT
P-8
P-9
P2P
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
R2-
ROL
RPZ
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
TLN
UKHRP
UV1
WOW
X7M
XBR
Z5R
3V.
AACTN
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
RIG
SDF
ABLVK
ABYKQ
AHPSJ
AJBFU
ZA5
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
0TZ
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c502t-8ac2174334bc152ff221837e055233e4b49379360df17bd3fbdacd52eb3c5d823
IEDL.DBID 7X7
ISSN 1470-2045
1474-5488
IngestDate Fri Jul 11 13:02:49 EDT 2025
Fri Jul 25 04:49:24 EDT 2025
Mon Jul 21 06:09:31 EDT 2025
Thu Apr 24 23:10:41 EDT 2025
Tue Jul 01 01:53:27 EDT 2025
Fri Feb 23 02:39:12 EST 2024
Tue Feb 25 20:02:55 EST 2025
Tue Aug 26 16:33:27 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Copyright © 2022 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c502t-8ac2174334bc152ff221837e055233e4b49379360df17bd3fbdacd52eb3c5d823
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 35240053
PQID 2644337003
PQPubID 46089
PageCount 12
ParticipantIDs proquest_miscellaneous_2636141500
proquest_journals_2644337003
pubmed_primary_35240053
crossref_primary_10_1016_S1470_2045_22_00058_4
crossref_citationtrail_10_1016_S1470_2045_22_00058_4
elsevier_sciencedirect_doi_10_1016_S1470_2045_22_00058_4
elsevier_clinicalkeyesjournals_1_s2_0_S1470204522000584
elsevier_clinicalkey_doi_10_1016_S1470_2045_22_00058_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-04-01
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle The lancet oncology
PublicationTitleAlternate Lancet Oncol
PublicationYear 2022
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Lo, Wang, Ko (bib25) 2012; 19
Chen, Tang, Sun (bib10) 2014; 36
Lee, Poon, Foo (bib26) 1992; 23
Guo, Tang, Mao (bib23) 2019; 125
Li, Yuan, Zhang (bib28) 2013; 119
Lv, Cao, Xia (bib16) 2021; 22
Cox, Stetz, Pajak (bib14) 1995; 31
Grégoire, Ang, Budach (bib12) 2014; 110
Bray, Ferlay, Soerjomataram, Siegel, Torre, Jemal (bib1) 2018; 68
Fayers, Aaronson, Bjordal (bib21) 2001
Tang, Mao, Liu (bib5) 2009; 115
Lee, Foo, Law (bib3) 1997; 3
Licitra, Mesía, Keilholz (bib30) 2016; 52
Chen, Chan, Le, Blanchard, Sun, Ma (bib2) 2019; 394
Sham, Cheung, Choy, Chan, Leong (bib27) 1993; 26
Lai, Li, Chen (bib15) 2011; 80
Sommat, Ong, Hussain (bib6) 2017; 98
Tang, Tang, Li (bib8) 2017; 69
King, Ahuja, Leung (bib4) 2000; 22
Pong, Urner, Fowler (bib17) 2021; 11
Al-Mamgani, van Rooij, Tans, Verduijn, Sewnaik, Baatenburg de Jong (bib31) 2013; 106
Tang, Chen, Mao (bib24) 2017; 15
Lee, Harris, Garden (bib7) 2009; 27
Chen, Ismaila, Chua (bib13) 2021; 39
Schoenfeld (bib19) 1982; 39
Tang, Chen, Guo (bib18) 2018; 19
Fisher, Copas, Tierney, Parmar (bib20) 2011; 64
Xiao, Dou, Li (bib9) 2019; 21
Li, Sun, Chen (bib11) 2012; 31
de Veij Mestdagh, Walraven, Vogel (bib32) 2020; 147
Mehanna, Robinson, Hartley (bib22) 2019; 393
Murphy (bib29) 2013; 11
Grégoire (10.1016/S1470-2045(22)00058-4_bib12) 2014; 110
Tang (10.1016/S1470-2045(22)00058-4_bib18) 2018; 19
Fisher (10.1016/S1470-2045(22)00058-4_bib20) 2011; 64
Xiao (10.1016/S1470-2045(22)00058-4_bib9) 2019; 21
Sommat (10.1016/S1470-2045(22)00058-4_bib6) 2017; 98
Tang (10.1016/S1470-2045(22)00058-4_bib8) 2017; 69
Schoenfeld (10.1016/S1470-2045(22)00058-4_bib19) 1982; 39
Murphy (10.1016/S1470-2045(22)00058-4_bib29) 2013; 11
Lee (10.1016/S1470-2045(22)00058-4_bib7) 2009; 27
Chen (10.1016/S1470-2045(22)00058-4_bib13) 2021; 39
Lee (10.1016/S1470-2045(22)00058-4_bib26) 1992; 23
Guo (10.1016/S1470-2045(22)00058-4_bib23) 2019; 125
Lo (10.1016/S1470-2045(22)00058-4_bib25) 2012; 19
Tang (10.1016/S1470-2045(22)00058-4_bib24) 2017; 15
Al-Mamgani (10.1016/S1470-2045(22)00058-4_bib31) 2013; 106
Sham (10.1016/S1470-2045(22)00058-4_bib27) 1993; 26
King (10.1016/S1470-2045(22)00058-4_bib4) 2000; 22
Chen (10.1016/S1470-2045(22)00058-4_bib2) 2019; 394
Lai (10.1016/S1470-2045(22)00058-4_bib15) 2011; 80
Li (10.1016/S1470-2045(22)00058-4_bib28) 2013; 119
de Veij Mestdagh (10.1016/S1470-2045(22)00058-4_bib32) 2020; 147
Lv (10.1016/S1470-2045(22)00058-4_bib16) 2021; 22
Licitra (10.1016/S1470-2045(22)00058-4_bib30) 2016; 52
Lee (10.1016/S1470-2045(22)00058-4_bib3) 1997; 3
Chen (10.1016/S1470-2045(22)00058-4_bib10) 2014; 36
Tang (10.1016/S1470-2045(22)00058-4_bib5) 2009; 115
Li (10.1016/S1470-2045(22)00058-4_bib11) 2012; 31
Pong (10.1016/S1470-2045(22)00058-4_bib17) 2021; 11
Cox (10.1016/S1470-2045(22)00058-4_bib14) 1995; 31
Fayers (10.1016/S1470-2045(22)00058-4_bib21) 2001
Mehanna (10.1016/S1470-2045(22)00058-4_bib22) 2019; 393
Bray (10.1016/S1470-2045(22)00058-4_bib1) 2018; 68
35654058 - Lancet Oncol. 2022 Jun;23(6):e241
35654056 - Lancet Oncol. 2022 Jun;23(6):e239
35951036 - Strahlenther Onkol. 2022 Nov;198(11):1042-1044
36096750 - Chin Clin Oncol. 2022 Jan;11(5):35
35240054 - Lancet Oncol. 2022 Apr;23(4):441-443
35654057 - Lancet Oncol. 2022 Jun;23(6):e240
References_xml – volume: 22
  start-page: 275
  year: 2000
  end-page: 281
  ident: bib4
  article-title: Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease
  publication-title: Head Neck
– volume: 11
  start-page: 149
  year: 2013
  end-page: 159
  ident: bib29
  article-title: To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer
  publication-title: J Support Oncol
– volume: 147
  start-page: 56
  year: 2020
  end-page: 63
  ident: bib32
  article-title: SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: a potentially practice-changing approach
  publication-title: Radiother Oncol
– volume: 64
  start-page: 949
  year: 2011
  end-page: 967
  ident: bib20
  article-title: A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners
  publication-title: J Clin Epidemiol
– volume: 23
  start-page: 261
  year: 1992
  end-page: 270
  ident: bib26
  article-title: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 39
  start-page: 840
  year: 2021
  end-page: 859
  ident: bib13
  article-title: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline
  publication-title: J Clin Oncol
– volume: 394
  start-page: 64
  year: 2019
  end-page: 80
  ident: bib2
  article-title: Nasopharyngeal carcinoma
  publication-title: Lancet
– volume: 69
  start-page: 68
  year: 2017
  end-page: 73
  ident: bib8
  article-title: The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement
  publication-title: Oral Oncol
– volume: 15
  start-page: 913
  year: 2017
  end-page: 919
  ident: bib24
  article-title: Validation of the 8th Edition of the UICC/AJCC Staging System for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era
  publication-title: J Natl Compr Canc Netw
– volume: 27
  start-page: 3684
  year: 2009
  end-page: 3690
  ident: bib7
  article-title: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225
  publication-title: J Clin Oncol
– volume: 26
  start-page: 787
  year: 1993
  end-page: 792
  ident: bib27
  article-title: Computed tomography evaluation of neck node metastases from nasopharyngeal carcinoma
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 31
  start-page: 1341
  year: 1995
  end-page: 1346
  ident: bib14
  article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 39
  start-page: 499
  year: 1982
  end-page: 503
  ident: bib19
  article-title: Sample-size formula for the proportional-hazards regression model
  publication-title: Biometrics
– volume: 115
  start-page: 680
  year: 2009
  end-page: 688
  ident: bib5
  article-title: The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging
  publication-title: Cancer
– volume: 98
  start-page: 574
  year: 2017
  end-page: 580
  ident: bib6
  article-title: Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 80
  start-page: 661
  year: 2011
  end-page: 668
  ident: bib15
  article-title: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 22
  start-page: 716
  year: 2021
  end-page: 726
  ident: bib16
  article-title: Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial
  publication-title: Lancet Oncol
– volume: 52
  start-page: 18
  year: 2016
  end-page: 23
  ident: bib30
  article-title: Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck
  publication-title: Oral Oncol
– year: 2001
  ident: bib21
  article-title: EORTC QLQ-C30 scoring manual
– volume: 36
  start-page: 468
  year: 2014
  end-page: 473
  ident: bib10
  article-title: Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy
  publication-title: Head Neck
– volume: 19
  start-page: 1001
  year: 2012
  end-page: 1008
  ident: bib25
  article-title: Salvage treatment for isolated regional failure of nasopharyngeal carcinoma after primary radiotherapy
  publication-title: Ann Surg Oncol
– volume: 11
  year: 2021
  ident: bib17
  article-title: Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics
  publication-title: BMJ Open
– volume: 31
  start-page: 579
  year: 2012
  end-page: 587
  ident: bib11
  article-title: Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation
  publication-title: Chin J Cancer
– volume: 106
  start-page: 359
  year: 2013
  end-page: 363
  ident: bib31
  article-title: A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration?
  publication-title: Radiother Oncol
– volume: 110
  start-page: 172
  year: 2014
  end-page: 181
  ident: bib12
  article-title: Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines
  publication-title: Radiother Oncol
– volume: 21
  start-page: 781
  year: 2019
  end-page: 789
  ident: bib9
  article-title: Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes
  publication-title: Clin Transl Oncol
– volume: 125
  start-page: 79
  year: 2019
  end-page: 89
  ident: bib23
  article-title: Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma
  publication-title: Cancer
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: bib1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
– volume: 119
  start-page: 3170
  year: 2013
  end-page: 3176
  ident: bib28
  article-title: A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma
  publication-title: Cancer
– volume: 19
  start-page: 461
  year: 2018
  end-page: 473
  ident: bib18
  article-title: Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
  publication-title: Lancet Oncol
– volume: 393
  start-page: 51
  year: 2019
  end-page: 60
  ident: bib22
  article-title: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
  publication-title: Lancet
– volume: 3
  start-page: 355
  year: 1997
  end-page: 361
  ident: bib3
  article-title: Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis
  publication-title: Hong Kong Med J
– volume: 19
  start-page: 461
  year: 2018
  ident: 10.1016/S1470-2045(22)00058-4_bib18
  article-title: Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30104-9
– volume: 31
  start-page: 579
  year: 2012
  ident: 10.1016/S1470-2045(22)00058-4_bib11
  article-title: Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation
  publication-title: Chin J Cancer
  doi: 10.5732/cjc.012.10095
– volume: 64
  start-page: 949
  year: 2011
  ident: 10.1016/S1470-2045(22)00058-4_bib20
  article-title: A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.11.016
– year: 2001
  ident: 10.1016/S1470-2045(22)00058-4_bib21
– volume: 393
  start-page: 51
  year: 2019
  ident: 10.1016/S1470-2045(22)00058-4_bib22
  article-title: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)32752-1
– volume: 394
  start-page: 64
  year: 2019
  ident: 10.1016/S1470-2045(22)00058-4_bib2
  article-title: Nasopharyngeal carcinoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)30956-0
– volume: 22
  start-page: 716
  year: 2021
  ident: 10.1016/S1470-2045(22)00058-4_bib16
  article-title: Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00075-9
– volume: 19
  start-page: 1001
  year: 2012
  ident: 10.1016/S1470-2045(22)00058-4_bib25
  article-title: Salvage treatment for isolated regional failure of nasopharyngeal carcinoma after primary radiotherapy
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-011-2018-3
– volume: 68
  start-page: 394
  year: 2018
  ident: 10.1016/S1470-2045(22)00058-4_bib1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 80
  start-page: 661
  year: 2011
  ident: 10.1016/S1470-2045(22)00058-4_bib15
  article-title: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2010.03.024
– volume: 115
  start-page: 680
  year: 2009
  ident: 10.1016/S1470-2045(22)00058-4_bib5
  article-title: The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging
  publication-title: Cancer
  doi: 10.1002/cncr.24049
– volume: 11
  year: 2021
  ident: 10.1016/S1470-2045(22)00058-4_bib17
  article-title: Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-044480
– volume: 147
  start-page: 56
  year: 2020
  ident: 10.1016/S1470-2045(22)00058-4_bib32
  article-title: SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: a potentially practice-changing approach
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2020.03.012
– volume: 3
  start-page: 355
  year: 1997
  ident: 10.1016/S1470-2045(22)00058-4_bib3
  article-title: Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis
  publication-title: Hong Kong Med J
– volume: 106
  start-page: 359
  year: 2013
  ident: 10.1016/S1470-2045(22)00058-4_bib31
  article-title: A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration?
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2012.12.014
– volume: 27
  start-page: 3684
  year: 2009
  ident: 10.1016/S1470-2045(22)00058-4_bib7
  article-title: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.9109
– volume: 31
  start-page: 1341
  year: 1995
  ident: 10.1016/S1470-2045(22)00058-4_bib14
  article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(95)00060-C
– volume: 22
  start-page: 275
  year: 2000
  ident: 10.1016/S1470-2045(22)00058-4_bib4
  article-title: Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease
  publication-title: Head Neck
  doi: 10.1002/(SICI)1097-0347(200005)22:3<275::AID-HED10>3.0.CO;2-N
– volume: 125
  start-page: 79
  year: 2019
  ident: 10.1016/S1470-2045(22)00058-4_bib23
  article-title: Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.31741
– volume: 21
  start-page: 781
  year: 2019
  ident: 10.1016/S1470-2045(22)00058-4_bib9
  article-title: Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-018-1988-z
– volume: 26
  start-page: 787
  year: 1993
  ident: 10.1016/S1470-2045(22)00058-4_bib27
  article-title: Computed tomography evaluation of neck node metastases from nasopharyngeal carcinoma
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(93)90493-F
– volume: 39
  start-page: 499
  year: 1982
  ident: 10.1016/S1470-2045(22)00058-4_bib19
  article-title: Sample-size formula for the proportional-hazards regression model
  publication-title: Biometrics
  doi: 10.2307/2531021
– volume: 23
  start-page: 261
  year: 1992
  ident: 10.1016/S1470-2045(22)00058-4_bib26
  article-title: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/0360-3016(92)90740-9
– volume: 69
  start-page: 68
  year: 2017
  ident: 10.1016/S1470-2045(22)00058-4_bib8
  article-title: The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2017.03.010
– volume: 39
  start-page: 840
  year: 2021
  ident: 10.1016/S1470-2045(22)00058-4_bib13
  article-title: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.03237
– volume: 36
  start-page: 468
  year: 2014
  ident: 10.1016/S1470-2045(22)00058-4_bib10
  article-title: Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy
  publication-title: Head Neck
  doi: 10.1002/hed.23314
– volume: 110
  start-page: 172
  year: 2014
  ident: 10.1016/S1470-2045(22)00058-4_bib12
  article-title: Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2013.10.010
– volume: 52
  start-page: 18
  year: 2016
  ident: 10.1016/S1470-2045(22)00058-4_bib30
  article-title: Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2015.10.020
– volume: 11
  start-page: 149
  year: 2013
  ident: 10.1016/S1470-2045(22)00058-4_bib29
  article-title: To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer
  publication-title: J Support Oncol
  doi: 10.12788/j.suponc.0005
– volume: 98
  start-page: 574
  year: 2017
  ident: 10.1016/S1470-2045(22)00058-4_bib6
  article-title: Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2017.03.007
– volume: 15
  start-page: 913
  year: 2017
  ident: 10.1016/S1470-2045(22)00058-4_bib24
  article-title: Validation of the 8th Edition of the UICC/AJCC Staging System for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2017.0121
– volume: 119
  start-page: 3170
  year: 2013
  ident: 10.1016/S1470-2045(22)00058-4_bib28
  article-title: A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.28201
– reference: 35654057 - Lancet Oncol. 2022 Jun;23(6):e240
– reference: 35951036 - Strahlenther Onkol. 2022 Nov;198(11):1042-1044
– reference: 35240054 - Lancet Oncol. 2022 Apr;23(4):441-443
– reference: 36096750 - Chin Clin Oncol. 2022 Jan;11(5):35
– reference: 35654058 - Lancet Oncol. 2022 Jun;23(6):e241
– reference: 35654056 - Lancet Oncol. 2022 Jun;23(6):e239
SSID ssj0017105
Score 2.6059356
Snippet The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional...
SummaryBackgroundThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides...
Summary Background The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 479
SubjectTerms Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Chemoradiotherapy
Chemoradiotherapy - adverse effects
Chemoradiotherapy - methods
Chemotherapy
Cisplatin
Clinical trials
Dermatomyositis
Dysphagia
Epstein-Barr virus
Hematology
Hematology, Oncology, and Palliative Medicine
Humans
Hypothyroidism
Intravenous administration
Lymph nodes
Lymphatic system
Metastases
Metastasis
Middle Aged
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Carcinoma - radiotherapy
Nasopharyngeal Neoplasms - pathology
Neck
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Patients
Quality of life
Radiation
Radiation therapy
Spinal cord
Survival
Throat cancer
Toxicity
Translation
Tumors
Young Adult
Title Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1470204522000584
https://www.clinicalkey.es/playcontent/1-s2.0-S1470204522000584
https://dx.doi.org/10.1016/S1470-2045(22)00058-4
https://www.ncbi.nlm.nih.gov/pubmed/35240053
https://www.proquest.com/docview/2644337003
https://www.proquest.com/docview/2636141500
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELWglRAXxDdbSmUkDiCtaWI7mywXBNVWFRIVAirtzXJsB1YsTprsgvhp_DtmHCe9UMolh8Rjr3YmM2_i8TxCns2MkZBJZExYkTNZyJTNs1wwoXXFK6R2sKHb5-ns5Ey-W2bL-MGti2WVg08MjtrWBr-RH2LgFiIHI3zdnDNkjcLd1UihcZ3sYusytOp8OSZcad6XMKYyTxi2Xb84wXP4abz5nPMXiFwKJi-LTZdhzxCDjm-TWxE80je9tu-Qa87fJTfex-3xe-T3Yt37L7ptGtcy78w3inUX247-RCLc_s6qbbEjAaqE1hUFCEi3fuXBUf1wlvZDPI0dV0FytflKvUa-A93-8l8AWlKDFES-_q5fUQ2TNM4zMCe3nlJfe4YVXu2qRl68KQ0li6EG1E0pREZbg2nBOjBb56iggTfkPjk7Xnw-OmGRm4GZLOEbVmgTkhkhSwMQoKo4Yq3cJRlktsLJUgLumYtZYqs0L62oSquNzTjk7iazBRcPyA78IPeIUF2AI5i7pHKllGU2L0oHaWsJybMuQONiQuSgFWVi43Lkz1irsUINlalQmYpzFZSp5IS8HMWavnPHVQKzQeVqOJYKjlRBbLlKMP-boOuiO-hUqjoY3Uvz0MQ-iIJkMUpGxNMjmf9ZdH-wSjWuc_GSTMjT8TFoFXeBtHf1FscIgGSQByQT8rC35vH_ATQu0S3v_Xvyx-Qmx1MgoYBpn-xs2q17AthsUx6EFxCuxVF6QHbfLk4_fPwD3880Ew
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxJstBYwEEkhrmtjOJouEECqttvRxoZV6M47jwKqLE5INVf8Ud_4dM86jF0q59Jr12NHOeOabeDwfIS8mxkjIJCImMhEzmciQTaNYMKF1znOkdsh8t8-DyexIfjqOjlfIr_4uDJZV9j7RO-qsMPiNfAMDtxAxGOH78gdD1ig8Xe0pNFqz2LVnp5Cy1e92PoJ-X3K-vXW4OWMdqwAzUcCXLNHGw3AhUwPBK885ooTYBhHkZMLKVELEnopJkOVhnGYiTzNtsohD1mmiLMFGB-Dyr-HL4I5KNoeSkjBuSyZDGQcM27yf3xja-Dw8fMX5a0RKCZMXxcKLsK6Pedu3ya0OrNIPrXXdISvW3SXX97vj-Hvk99ai9Ze0KUtbMWfNCcU6j6amp0i82z6ZVxV2QEAToEVOAXLSxs0dOMafNqPtEEe7Dq8gOV9-o04jv4KuztxXgLLUIOWRK77rt1TDJKV1DMzXLsbUFY5hRVk1L5CHb0x9iaSvObVjCpE4K8CUYR2YrbZUUM9Tcp8cXYnWHpBVeCH7iFCdgOOZ2iC3qZRpNE1SC2lyCsm6TkCpYkRkrxVlukbpyNexUENFHCpToTIV58orU8kReTOIlW2nkMsEJr3KVX8NFhy3glh2mWD8N0Fbd-6nVqGqYXQrzX3TfC8Kkskg2SGsFjn9z6LrvVWqYZ3zTTkiz4efQat46qSdLRocIwACQt4RjMjD1pqH_wfQv8QwsPbvyZ-RG7PD_T21t3Ow-5jc5HgDxRdPrZPVZdXYJ4ALl-lTvxkp-XLVu_8PGh1tlQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIU28oPFdGGAkkECqWWI7TYqEENpWbQwmJJi0N89xHFZRnJA0TPvT4K_jzvnYC2O87DX12W3vfPe7-Hw_Qp5NjJGQSURMZCJmMpEhm0axYELrnOdI7ZD5bp8Hk91D-f4oOlohv_u7MFhW2ftE76izwuA78k0M3ELE-N4t78oiPm3P3pY_GDJI4UlrT6fRmsi-PTuF9K1-s7cNun7O-Wzny9Yu6xgGmIkCvmSJNh6SC5kaCGR5zhExxDaIID8TVqYSovdUTIIsD-M0E3maaZNFHDJQE2UJNj0A938tFvCb8Jb61lBeEsZt-WQo44Bhy_fz20Obn4eHLzh_iagpYfKiuHgR7vXxb7ZObnTAlb5rLe0mWbHuFln72B3N3ya_dhat76RNWdqKOWu-Uaz5aGp6iiS87ZN5VWE3BDQHWuQU4Cdt3NyBk_xpM9oOcbTr9gqS8-UJdRq5FnR15r4CrKUG6Y9c8V2_phomKa1jYMp2MaaucAyry6p5gZx8Y-rLJX39qR1TiMpZAWYN68BstaWCes6SO-TwSrR2l6zCF7L3CdUJOKGpDXKbSplG0yS1kDKnkLjrBKxNjIjstaJM1zQduTsWaqiOQ2UqVKbiXHllKjkirwaxsu0acpnApFe56q_EghNXENcuE4z_JmjrzhXVKlQ1jG6luW-g70VBMhkkO7TVoqj_WXSjt0o1rHO-QUfk6fAxaBVPoLSzRYNjBMBByEGCEbnXWvPw_0AmIDEkPPj35E_IGux79WHvYP8huc7xMoqvo9ogq8uqsY8AIi7Tx34vUnJ81Zv_D5EMccs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elective+upper-neck+versus+whole-neck+irradiation+of+the+uninvolved+neck+in+patients+with+nasopharyngeal+carcinoma%3A+an+open-label%2C+non-inferiority%2C+multicentre%2C+randomised+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Tang%2C+Ling-Long&rft.au=Huang%2C+Cheng-Long&rft.au=Zhang%2C+Ning&rft.au=Jiang%2C+Wei&rft.date=2022-04-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=23&rft.issue=4&rft.spage=479&rft.epage=490&rft_id=info:doi/10.1016%2FS1470-2045%2822%2900058-4&rft.externalDocID=S1470204522000584
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204522X00041%2Fcov150h.gif